SCOPUS 정보 검색 플랫폼

Annals of Surgical Oncology

Volumn 19, Issue 13, 2012, Pages 3998-4000

The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: Hope or hoax?

(1) Herzog, Thomas J a

a Columbia University College of Physicians and Surgeons ^* (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CATHETERIZATION; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DISEASE FREE INTERVAL; HEATED INTRAPERITONEAL CHEMOTHERAPY; HUMAN; HYPERTHERMIC THERAPY; LAPAROSCOPY; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 84876458971 PISSN: 10689265 EISSN: 15344681 Source Type: Journal
DOI: 10.1245/s10434-012-2521-1 Document Type: Review

Times cited : (12)

References (6)

1
- 33847242677
- A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer
- DOI 10.1111/j.1525-1438.2006.00846.x
- Hess LM, Benham-Hutchins M, Herzog TJ, Hsu CH, Malone DC, Skrepnek GH, et al. A meta-analysis of the efficacy of intraperi-toneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer. 2007;17:561-70. (Pubitemid 46744010)
- (2007) International Journal of Gynecological Cancer , vol.17 , Issue.3 , pp. 561-570
- Hess, L.M.¹ Benham-Hutchins, M.² Herzog, T.J.³ Hsu, C.-H.⁴ Malone, D.C.⁵ Skrepnek, G.H.⁶ Slack, M.K.⁷ Alberts, D.S.⁸

2
- 68449087111
- The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer
- Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist. 2009;14:683-94.
- (2009) Oncologist. , vol.14 , pp. 683-694
- Helm, C.W.¹

3
- 84876503657
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: A multicenter prospective study of 246 patients
- doi:10.1245/s10434-012-2510-4
- Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter prospective study of 246 patients. Ann Surg Oncol. doi:10.1245/s10434-012-2510-4.
- Ann Surg Oncol
- Bakrin, N.¹ Cotte, E.² Golfier, F.³ Gilly, F.N.⁴ Freyer, G.⁵ Helm, W.⁶

4
- 77954106351
- Hyperthermic intraperitoneal chemotherapy added to the treatment of ovarian cancer. A review of achieved results and complications
- Dovern E, de Hingh IH, Verwaal VJ, Van Driel WJ, Nienhuijs SW. Hyperthermic intraperitoneal chemotherapy added to the treatment of ovarian cancer. A review of achieved results and complications. Eur J Gynaecol Oncol. 2010;31:256-61.
- (2010) Eur J Gynaecol Oncol. , vol.31 , pp. 256-261
- Dovern, E.¹ De Hingh, I.H.² Verwaal, V.J.³ Van Driel, W.J.⁴ Nienhuijs, S.W.⁵

5
- 84867521567
- Survival benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: Review of evidence
- May 14 [Epub ahead of print]
- Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, et al. Survival benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 2012; May 14 [Epub ahead of print].
- (2012) Curr Pharm Des.
- Mulier, S.¹ Claes, J.P.² Dierieck, V.³ Amiel, J.O.⁴ Pahaut, J.P.⁵ Marcelis, L.⁶

6
- 84876489531
- ClinicalTrials.gov. Accessed 6 June 2012
- ClinicalTrials.gov. 2012. http://clinicaltrials.gov/. Accessed 6 June 2012.
- (2012)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.